Persistent Staphylococcus aureus bacteremia: Incidence and outcome trends over time

References

• Hawkins C, Huang J, Jin N, Noskin GA, Zembower TR, Bolon M. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcome. Arch Intern Med 2007; 167: 1861–7
   PubMedGoogle Scholar
• Khatib R, Johnson LB, Fakih MG, Riederer K, Khosrovaneh A, Tabriz MS, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006; 38: 7–14
   PubMed Web of Science ®Google Scholar
• Fowler VG, Jr, Sakoulas G, McIntyre LM, Meka VG, Arbeit RD, Cabel CH, et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbiocidal protein. J Infect Dis 2004; 190: 1140–9
   PubMed Web of Science ®Google Scholar
• Reymann MT, Holley HP, Jr, Cobbs CG. Persistent bacteremia in staphylococcal endocarditis. Am J Med 1978; 65: 729–37
   PubMed Web of Science ®Google Scholar
• Siegma-Igra Y, Reich P, Orni-Wasserlauf R, Schwartz D, Giladi M. The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteremia. Scand J Infect Dis 2005; 37: 572–8
   PubMedGoogle Scholar
• Johnson LB, Almoujahed MO, Ilg K, Maolood L, Khatib R. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis 2003; 35: 782–9
   PubMed Web of Science ®Google Scholar
• Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agent Chemother 2007; 51: 2528–6
   Web of Science ®Google Scholar
• Howden BP, Johnson PDR, Ward PB, Stinear TP, Davies JK. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agent Chemother 2006; 50: 3039–47
   PubMed Web of Science ®Google Scholar
• Khosrovaneh A, Riederer K, Saeed S, Tabriz MS, Shah AR, Hanna MM, et al. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2004; 38: 1328–30
   PubMed Web of Science ®Google Scholar
• Khatib R, Riederer K, Saeed S, Johnson LB, Fakih MG, Sharma M, et al. Time to positivity in Staphylococcus aureus bacteremia: possible correlation with the source and outcome of infection. Clin Infect Dis 2005; 41: 594–8
   PubMed Web of Science ®Google Scholar
• Bakri FG, Al-Hommos NA, Shehabi A, Naffa RG, Cui L, Hiramatsu K. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in a patient with erythrodermic psoriasis. Scand J Infect Dis 2007; 39: 457–60
   PubMed Web of Science ®Google Scholar
• Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633–8
   PubMed Web of Science ®Google Scholar
• Fowler VG, Jr, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163: 2066–72
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Coyle EA, Raad II, Prince RA, Lewis RE. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of Gram-positive catheter-related bacteremia. J Antimicrob Chemother 2005; 55: 792–5
   PubMed Web of Science ®Google Scholar
• Veeh RH, Shirtliff ME, Petik JR, Flood JA, Davis CC, Seymour JL, et al. Detection of Staphylococcus aureus biofilm on tampons and menses components. J Infect Dis 2003; 188: 519–30
   PubMed Web of Science ®Google Scholar
• Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, et al. Comparative activity of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus aureus bacteremic isolates embedded in biofilm. Antimicrob Agent Chemother 2007; 51: 1656–60
   PubMed Web of Science ®Google Scholar
• Cirioni O, Giacometti A, Ghiselli R, Dell 'Acqua G, Orlando F, Mocchegiani F, et al. RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections. J Infect Dis 2006; 193: 180–6
   PubMed Web of Science ®Google Scholar